Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CET

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum(TM) (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum(TM) MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum(TM) MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt(®)

For full U.S. Prescribing Information for Fanapt(®), including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
11/15 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
11/13 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
11/10 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
11/10 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
11/08 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
11/07 VANDA PHARMACEUTICALS : reports 3Q loss
11/07 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
11/07 VANDA PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
11/07 VANDA PHARMACEUTICALS INC. : to Host Earnings Call
11/02 VANDA PHARMACEUTICALS : to Announce Third Quarter 2017 Financial Results on Nove..
More news
News from SeekingAlpha
11/10 Vanda strikes out in appeal of thumbs down from European advisory group on Fa..
11/07 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - ..
11/07 Vanda Pharmaceuticals beats by $0.08, misses on revenue
11/06 Notable earnings after Tuesday?s close
10/31 BIOSCIENCE CATALYSTS : Global Blood Therapeutics And Vanda Pharmaceuticals